MX2018009867A - Metodos que comprenden una dosificacion intermitente fija de cediranib. - Google Patents
Metodos que comprenden una dosificacion intermitente fija de cediranib.Info
- Publication number
- MX2018009867A MX2018009867A MX2018009867A MX2018009867A MX2018009867A MX 2018009867 A MX2018009867 A MX 2018009867A MX 2018009867 A MX2018009867 A MX 2018009867A MX 2018009867 A MX2018009867 A MX 2018009867A MX 2018009867 A MX2018009867 A MX 2018009867A
- Authority
- MX
- Mexico
- Prior art keywords
- cediranib
- administration
- methods
- composition
- consecutive days
- Prior art date
Links
Classifications
-
- G01N33/575—
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
En la presente se divulgan métodos que comprenden ciclos repetidos de administración de una composición que comprende cediranib de acuerdo con un patrón posológico intermitente fijo que comprende la administración de una cantidad eficaz de la composición que comprende cediranib en uno o más días consecutivos de un ciclo seguidos por uno o más días consecutivos de descanso en los cuales no se administra dicha composición, y se pueden utilizar como monoterapia o pueden comprender la administración de una o más terapias o fármacos asociados y se pueden utilizar en la terapia combinada. Tales métodos pueden producir un efecto antiangiogénico y/o reductor de la permeabilidad vascular, tratar al menos un estado patológico asociado con la angiogénesis, reducir la dosis total de cediranib requerida para proporcionar una inhibición de VEGF eficaz, reducir los eventos adversos y toxicidad debidos a la administración de cediranib, mantener la actuación sobre la ruta de VEGF a pesar de la reducción de las dosis totales de cediranib, y/o incrementar la reparación de tejido sano, no canceroso durante el tratamiento de cáncer utilizando terapias combinadas.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662295421P | 2016-02-15 | 2016-02-15 | |
| PCT/US2017/017804 WO2017142871A1 (en) | 2016-02-15 | 2017-02-14 | Methods comprising fixed intermittent dosing of cediranib |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018009867A true MX2018009867A (es) | 2019-05-27 |
Family
ID=59625551
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018009867A MX2018009867A (es) | 2016-02-15 | 2017-02-14 | Metodos que comprenden una dosificacion intermitente fija de cediranib. |
| MX2023007826A MX2023007826A (es) | 2016-02-15 | 2018-08-14 | Metodos que comprenden una dosificacion intermitente fija de cediranib. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023007826A MX2023007826A (es) | 2016-02-15 | 2018-08-14 | Metodos que comprenden una dosificacion intermitente fija de cediranib. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20210322415A1 (es) |
| EP (2) | EP4071174A1 (es) |
| JP (2) | JP6865762B2 (es) |
| KR (1) | KR102830910B1 (es) |
| CN (1) | CN109073650A (es) |
| AU (1) | AU2017221268B2 (es) |
| CA (1) | CA3014674C (es) |
| DK (1) | DK3417294T3 (es) |
| ES (1) | ES2906813T3 (es) |
| HU (1) | HUE058114T2 (es) |
| MA (1) | MA44251A (es) |
| MX (2) | MX2018009867A (es) |
| PL (1) | PL3417294T3 (es) |
| RU (1) | RU2740849C2 (es) |
| TW (1) | TWI827530B (es) |
| WO (1) | WO2017142871A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2019013373A (es) | 2017-05-09 | 2020-08-03 | Tesaro Inc | Terapias de combinación para tratar cáncer. |
| MA49144A (fr) | 2017-05-18 | 2020-03-25 | Tesaro Inc | Polythérapies pour le traitement du cancer |
| WO2019067978A1 (en) | 2017-09-30 | 2019-04-04 | Tesaro, Inc. | POLYTHERAPIES FOR THE TREATMENT OF CANCER |
| EP3691685A1 (en) | 2017-10-06 | 2020-08-12 | Tesaro Inc. | Combination therapies and uses thereof |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| PL205557B1 (pl) | 1999-02-10 | 2010-05-31 | Astrazeneca Ab | Pochodne indolu |
| BR0111230A (pt) | 2000-05-31 | 2003-06-10 | Astrazeneca Ab | Composto, e, uso e processo para a preparação do mesmo |
| UA73993C2 (uk) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
| BR0112224A (pt) | 2000-07-07 | 2003-06-10 | Angiogene Pharm Ltd | Composto, composição farmacêutica, uso de um composto ou de um sal, solvato ou pró-droga farmaceuticamente aceitável do mesmo, e, processo para preparar um composto |
| SK52003A3 (en) | 2000-07-07 | 2003-07-01 | Angiogene Pharm Ltd | Colchinol derivatives as angiogenesis inhibitors, method for their preparation and pharmaceutical composition comprising the same |
| JP2005530734A (ja) * | 2002-04-15 | 2005-10-13 | スローン − ケッタリング インスティチュート フォー キャンサー リサーチ | 癌の処置のための併用療法 |
| GB0330002D0 (en) | 2003-12-24 | 2004-01-28 | Astrazeneca Ab | Quinazoline derivatives |
| KR20070073813A (ko) * | 2004-09-27 | 2007-07-10 | 아스트라제네카 아베 | Ａｚｄ2171 및 이마티닙을 포함하는 암의 병합 요법 |
| US20090035317A1 (en) * | 2007-01-12 | 2009-02-05 | Daugherty Patrick S | Peptides binding to vascular endothelial growth factor |
| BRPI0908100A2 (pt) * | 2008-02-21 | 2015-10-06 | Astrazeneca Ab | produto combinação, uso de um composto, e, método de tratar câncer |
| MX2011008221A (es) * | 2009-02-04 | 2011-08-17 | Bipar Sciences Inc | Tratamiento de cancer de pulmon con un compuesto de nitrobenzamida en combinacion con un inhibidor de un factor de crecimieno. |
| HRP20171653T1 (hr) | 2009-11-24 | 2017-12-15 | Medimmune Limited | Vezna sredstva koja služe ciljano protiv b7-h1 |
| CA2854926A1 (en) * | 2011-11-08 | 2013-05-16 | Intellikine, Llc | Treatment regimens using multiple pharmaceutical agents |
| JP6184423B2 (ja) * | 2012-05-18 | 2017-08-23 | 大日本住友製薬株式会社 | カルボン酸化合物 |
| US10034939B2 (en) * | 2012-10-26 | 2018-07-31 | The University Of Chicago | Synergistic combination of immunologic inhibitors for the treatment of cancer |
| CN106456724A (zh) * | 2013-12-20 | 2017-02-22 | 博德研究所 | 使用新抗原疫苗的联合疗法 |
| NO2714752T3 (es) * | 2014-05-08 | 2018-04-21 | ||
| TWI716362B (zh) * | 2014-10-14 | 2021-01-21 | 瑞士商諾華公司 | 針對ｐｄ－ｌ１之抗體分子及其用途 |
-
2017
- 2017-02-14 ES ES17753704T patent/ES2906813T3/es active Active
- 2017-02-14 RU RU2018131377A patent/RU2740849C2/ru active
- 2017-02-14 CN CN201780011505.XA patent/CN109073650A/zh active Pending
- 2017-02-14 JP JP2018542709A patent/JP6865762B2/ja active Active
- 2017-02-14 US US16/077,720 patent/US20210322415A1/en not_active Abandoned
- 2017-02-14 MX MX2018009867A patent/MX2018009867A/es unknown
- 2017-02-14 DK DK17753704.0T patent/DK3417294T3/da active
- 2017-02-14 EP EP21211394.8A patent/EP4071174A1/en active Pending
- 2017-02-14 TW TW106104799A patent/TWI827530B/zh active
- 2017-02-14 CA CA3014674A patent/CA3014674C/en active Active
- 2017-02-14 WO PCT/US2017/017804 patent/WO2017142871A1/en not_active Ceased
- 2017-02-14 KR KR1020187024215A patent/KR102830910B1/ko active Active
- 2017-02-14 PL PL17753704T patent/PL3417294T3/pl unknown
- 2017-02-14 HU HUE17753704A patent/HUE058114T2/hu unknown
- 2017-02-14 EP EP17753704.0A patent/EP3417294B8/en active Active
- 2017-02-14 AU AU2017221268A patent/AU2017221268B2/en active Active
- 2017-02-14 MA MA044251A patent/MA44251A/fr unknown
-
2018
- 2018-08-14 MX MX2023007826A patent/MX2023007826A/es unknown
-
2021
- 2021-04-06 JP JP2021064539A patent/JP7271594B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| RU2018131377A (ru) | 2020-03-17 |
| AU2017221268A1 (en) | 2018-08-30 |
| US20210322415A1 (en) | 2021-10-21 |
| RU2740849C2 (ru) | 2021-01-21 |
| WO2017142871A8 (en) | 2018-06-14 |
| PL3417294T3 (pl) | 2022-05-09 |
| EP3417294B8 (en) | 2022-05-04 |
| CA3014674C (en) | 2024-06-18 |
| JP2021105039A (ja) | 2021-07-26 |
| JP2019504860A (ja) | 2019-02-21 |
| TWI827530B (zh) | 2024-01-01 |
| KR20180125456A (ko) | 2018-11-23 |
| HUE058114T2 (hu) | 2022-07-28 |
| WO2017142871A1 (en) | 2017-08-24 |
| EP3417294B1 (en) | 2021-12-01 |
| MA44251A (fr) | 2018-12-26 |
| ES2906813T3 (es) | 2022-04-20 |
| KR102830910B1 (ko) | 2025-07-04 |
| RU2018131377A3 (es) | 2020-06-02 |
| TW201906610A (zh) | 2019-02-16 |
| MX2023007826A (es) | 2023-07-07 |
| EP4071174A1 (en) | 2022-10-12 |
| CN109073650A (zh) | 2018-12-21 |
| EP3417294A1 (en) | 2018-12-26 |
| EP3417294A4 (en) | 2019-08-14 |
| AU2017221268B2 (en) | 2024-02-15 |
| JP7271594B2 (ja) | 2023-05-11 |
| CA3014674A1 (en) | 2017-08-24 |
| DK3417294T3 (da) | 2022-02-21 |
| JP6865762B2 (ja) | 2021-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2023000846A1 (es) | Terapia de combinación que incluye inhibidor de krasg12c y agente farmacéuticamente activo para tratar cáncer | |
| MX2021013830A (es) | Inhibidores de ezh2 para tratar linfomas. | |
| BR112017011536A2 (pt) | terapias de combinação | |
| BR112017014067A2 (pt) | composição para tratar doenças relacionadas a il-6 | |
| JOP20160092B1 (ar) | علاج البيتا ثلاسيميا باستخدام مصطبة لجائنية | |
| MX2015013355A (es) | Terapia que involucra anticuerpos contra claudina 18.2 para el tratamiento de cancer. | |
| MX2017012991A (es) | Combinaciones de amisulprida y otro antiemetico para tratar nausea y vomito. | |
| NI201400104A (es) | Esketamina para el tratamiento de la depresión refractaria al tratamiento o resistente al tratamiento | |
| ECSP14012676A (es) | Compuestos de carbamato y preparación y uso de los mismos | |
| CO2017007662A2 (es) | Terapias de combinación para el tratamiento de cánceres | |
| MX2016004580A (es) | Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia. | |
| MX380767B (es) | Métodos para reducir el riesgo cardiovascular. | |
| MX2014002171A (es) | Tratamientos de combinacion para hepatitis c. | |
| MX2017000627A (es) | Metodos para tratar pacientes con hipercolesterolemia familiar heterocigota (hfhe). | |
| MX2017000628A (es) | Metodos para tratar pacientes de alto riesgo cardiovascular con hipercolesterolemia. | |
| CO6382135A2 (es) | Terapia especifica y medicamento que usan ligando de integrina para tratar cancer | |
| MX2018009867A (es) | Metodos que comprenden una dosificacion intermitente fija de cediranib. | |
| MX2017006938A (es) | Terapia de combinacion para el tratamiento de cancer. | |
| MX381440B (es) | Composicion farmaceutica para tratar colitis ulcerativa. | |
| AR103118A1 (es) | Tratamientos médicos basados en anamorelina | |
| MX2016015437A (es) | Combinacion que comprende un glucocorticoide y edo-s101. | |
| MX2017008486A (es) | Combinaciones del inhibidor de tirosina cinasa de bruton (btk) y regimenes de dosificacion. | |
| PH12017502046A1 (en) | Salts and prodrugs of 1-methyl-d-tryptophan | |
| MX2018013873A (es) | Irinotecan nanoliposomico para usarse en el tratamiento del cancer de pulmon de celulas pequeñas. | |
| EA201692278A1 (ru) | Комбинации формотерола и будесонида для лечения хобл |